Full text

Turn on search term navigation

© 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Background

The real-world outcomes of edoxaban treatment in patients with atrial fibrillation (AF) were analyzed in the ETNA-AF (Edoxaban Treatment in Routine Clinical Practice) study involving data from multiple regional registries. This report addresses effectiveness and safety of edoxaban in the Korean ETNA-AF population.

Methods

One-year data from 1887 Korean ETNA-AF participants were analyzed according to edoxaban dose and patient age and compared with results of other ETNA-AF registries.

Results

Approximately 70% of patients received the recommended doses of edoxaban (60 mg/30 mg); non-recommended 60 mg and 30 mg doses were prescribed to 9.6% and 19.8% of the patients, respectively. The proportions of reference age (<65 years), youngest-old (65–74 years) and middle-old/oldest-old (≥75 years) groups were 21.4%, 40.2%, and 38.4%, respectively. Incidence of major or clinically relevant nonmajor bleeding was similar within dose (0.57%–1.71%) and age subgroups (1.26%–1.63%). Incidence of net clinical outcome, a composite of stroke, systemic embolic event, major bleeding, and all-cause mortality, was also comparable among dose subgroups (1.14%–3.10%) and age subgroups (2.28%–2.78%). The percentage of Korean patients receiving non-recommended 30 mg (19.8%) was over twice that of the European population (8.4%). However, the clinical outcomes were generally similar among different populations included in the ETNA-AF study.

Conclusions

The outcomes in the Korean ETNA-AF population are like those in the global ETNA-AF population, with overall low event rates of stroke, major bleeding and all-cause mortality across age and dose subgroups. Edoxaban can be used effectively and safely in specific populations of Korean AF patients, including the elderly.

Details

Title
Edoxaban treatment in atrial fibrillation in routine clinical care: One-year outcomes of the prospective observational ETNA-AF study in South Korean patients
Author
Choi, Eue-Keun 1   VIAFID ORCID Logo  ; Choi, Jong-Il 2   VIAFID ORCID Logo  ; Park, Hyoung-Seob 3   VIAFID ORCID Logo  ; Hwang, Gyo-Seung 4 ; Joung, Boyoung 5   VIAFID ORCID Logo  ; Jong-Youn, Kim 6 ; Dae-Hyeok, Kim 7 ; Dong Gu Shin 8 ; Park, Hyung Wook 9 

 Department of Internal Medicine, Seoul National University College of Medicine, Seoul National, University Hospital, Seoul, South Korea 
 Department of Internal Medicine, Korea University College of Medicine, Korea University Anam Hospital, Seoul, South Korea 
 Department of Internal Medicine, Keimyung University College of Medicine, Cardiovascular Center, Keimyung University Dongsan Hospital, Daegu, South Korea 
 Department of Internal Medicine, Ajou University School of Medicine, Ajou University Hospital, Suwon, South Korea 
 Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, South Korea 
 Department of Internal Medicine, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, South Korea 
 Department of Internal Medicine, Inha University College of Medicine, Inha University Hospital, Incheon, South Korea 
 Department of Internal Medicine, Yeungnam University College of Medicine, Yeungnam University Medical Center, Daegu, South Korea 
 Department of Internal Medicine, Chonnam National University School of Medicine, Chonnam National University Hospital, Gwangju, South Korea 
Pages
546-555
Section
ORIGINAL ARTICLES
Publication year
2023
Publication date
Aug 2023
Publisher
John Wiley & Sons, Inc.
ISSN
1880-4276
e-ISSN
1883-2148
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2847164267
Copyright
© 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.